Purdue Canada acquires Merck's ophthalmology portfolio
Purdue Canada has diversified its range of products by acquiring Merck & Co’s (NYSE: MRK) ophthalmology portfolio in a multi-regional framework agreement led by Mundipharma.
This acquisition agreement will give Purdue Canada marketing rights to Merck's ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension.
It forms part of the Mundipharma Ophthalmology Products Agreement that includes Australia, Latin America, Middle East, Africa and New Zealand. Just last week (The Pharma Letter December 3), Mundipharma signed an agreement with MSD, the operating name for US pharma giant Merck & Co outside the USA and Canada, to acquire MSD's ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze